Background. Trimethoprim-sulfamethoxazole (TMP-SMZ) has been used extensively for the prevention of Pneumocystis carinii (also referred to as "Pneumocystis jiroveci") pneumonia (PCP) and other opportunistic infections in human immunodeficiency virus (HIV)-infected children. Because the efficacy of TMP-SMZ for treatment of bacterial infections is limited, it is sometimes poorly tolerated, and there is risk of emergence of drug-resistant strains associated with widespread use, we evaluated a regimen that included atovaquone and azithromycin.
trimethoprim-sulfamethoxazole (TMP-SMZ) has been used for 125 years for the prevention of Pneumocystis carinii (also referred to as "Pneumocystis jiroveci") pneumonia (PCP) in immunocompromised patients [1] , including those with AIDS [2] [3] [4] [5] [6] . Less appreciated is the fact that the broad-spectrum antibacterial activity of TMP-SMZ prophylaxis also impacts favorably on bacterial infections in patients with AIDS [7, 8] and patients without AIDS [1, 9] . Thus, TMP-SMZ has been used in hundreds of thousands of patients worldwide over long periods of time and often with intermittent dose schedules.
Unlike other immunocompromised hosts, some HIVinfected adults and children experience a high rate of adverse reactions to TMP-SMZ, at times precluding its use [10] . The extensive use of TMP-SMZ, often given only 3 days per week, provides a basis for the development of drug resistance in both P. carinii and bacteria. Bacterial infections are now the most common serious threat to HIV-infected infants and children. Furthermore, an equally effective and safe prophylaxis regimen is needed for infants and children who cannot tolerate TMP-SMZ. We chose the combination of atovaquone and azithromycin for evaluation, because each of the drugs is known to be safe in HIV-infected adults and children, they have similar pharmacokinetic parameters, atovaquone has a mode of action and molecular target different from TMP-SMZ, and azithromycin extends the antibacterial spectrum to include Mycobacterium avium complex (MAC).
METHODS

Study design and entry criteria.
The study was a randomized, double-blind, placebo-controlled trial comparing atovaquoneazithromycin and TMP-SMZ for the prevention of serious bacterial infection in HIV-infected children during the period of March 1995 through June 2000 at 70 participating Pediatric AIDS Clinical Trials Group (PACTG) sites. The primary objectives were to determine whether the efficacy of atovaquoneazithromycin (atovaquone, 30 mg/kg q.d.; azithromycin, 5 mg/ kg q.d.) is equivalent to that of TMP-SMZ (TMP, 5 mg/kg q.d.; SMZ, 25 mg/kg q.d.) for efficacy in preventing serious bacterial infection and to determine and compare the long-term safety and tolerance of these treatments. The secondary objectives were to observe and compare breakthrough rates of PCP, MAC infection, and nonserious bacterial infections. Study subjects were stratified by previous use of TMP-SMZ and intravenous immunoglobulin (IVIG) . When a serious bacterial infection end point (a second serious bacterial infection) was reached, a serious treatment-related toxicity (1 grade 4 event or 2 grade 3 events) was identified, or PCP occurred, the patient was crossedover to the alternative study group for subsequent prophylaxis.
The study was planned for 280 patients per arm. With Data Safety Management Board approval (National Institute of Allergy and Infectious Diseases [NIAID]; Bethesda, MD), the study was terminated after enrollment of 369 patients, who were observed for a median of 3 years because of the limited availability of eligible pediatric subjects. The protocol and consent forms were approved by a local institutional review board for each site and by the PACTG at the NIAID.
Criteria for enrollment included age of 3 months to 19 years; documented evidence of HIV-1 infection, as defined by Centers for Disease Control and Prevention (CDC) guidelines [11] ; absence of any chronic infection requiring treatment; and risk for development of PCP, as defined by the CDC guidelines [12] . Risk factors for PCP included the following: for children aged 1-5 years, a CD4 lymphocyte count of !500 cells/mm 3 Patients were evaluated clinically and with standard protocoldriven hematological and blood chemistry laboratory studies every 4-8 weeks. Adverse events were assessed by the standard NIAID Division of AIDS Toxicity Table for Grading Severity of Pediatric Adverse Experiences. An independent data safety management board was appointed by the NIAID to monitor the study. Patients and parents were questioned at clinic visits about compliance with treatment and acceptability of study drug administration. Concurrent use of IVIG was permitted and was defined as the administration at a frequency of every р4 weeks for у2 consecutive months.
Serious bacterial infections and other primary opportunistic infection end points.
The following were protocol-designated serious bacterial infections: bacteremia, pneumonia, pyelonephritis, septic thrombophlebitis, arthritis, endocarditis, epiglottis, internal organ abscess, meningitis, myositis, osteomyelitis, mastoiditis, sinusitis, salpingitis, and tracheitis. Criteria used for the diagnoses of specific infections were those developed by the PACTG for clinical trials ("Pediatric Diagnoses for Determining Study Endpoints"; NIAID Division of AIDS, unpublished data). Infections with the etiology documented by culture or histologic analysis were designated "proven"; those without documentation were designated "presumptive." A presumptive diagnosis of sinusitis required evidence of disease by radiography or CT reviewed by a single central radiologist blinded to treatment regimens and case review by study team. An end point was reached when proven PCP and MAC infection were initially identified. Nonserious bacterial infections (e.g., otitis media, impetigo, pharyngitis, and vaginitis) were not criteria for crossover to the alternative study drug regimen.
Analysis of data. For each patient, we computed the observed rate of events, which is the number of events for the patient during his/her follow-up time (years) divided by his/ her follow-up time. "Intent-to-treat" referred to the time from randomization to the off-study date. "As-treated follow-up" was the time from randomization to the date of permanent discontinuation of originally randomized treatment. The primary efficacy comparison between the 2 arms was based on the difference of the 2 sample means of those rates. The 95% CI for the difference of 2 mean rates was based on the standard t statistic.
In addition to serious bacterial infection-related events, the secondary efficacy analysis included patient-related episodes of PCP, MAC infection, and nonserious bacterial infection-related (14) 25 (14) 27 (15) . 24 3-12 286 (78) 149 (81) 137 (76) у13 28 (8) 10 (5) 18 (10 death. We computed the rate for each patient with respect to the compound events.
We compared the 2 treatment arms with respect to the recurrent event time observations by the method of Wei et al. (the WLW method) [13] . Specifically, we assumed that the hazard functions for the first event times between the 2 groups were proportional and then combined the estimates of the 2 relative risks with respect to these 2 event times. The method of Andersen and Gill [14] for analysis of recurrent events with time-dependent covariates was used to evaluate the effects of antiretroviral drugs on the infection rate.
Toxicity end points. Criteria for toxicity end points and crossover included a second toxicity event of grade 3 after resolution of the first event, a grade 3 toxicity event that did not resolve to a grade of р2 in р28 days, a grade 4 toxicity event associated with use of the study drug, anemia necessitating 13 transfusions in a 90-day period to maintain a hemoglobin grade of р2, or recurrence of grade 3 neutropenia after administration of cytokines.
RESULTS
Enrollment
Three hundred sixty-nine patients were enrolled in the study, but 3 patients never started treatment and were excluded from the analysis. Differences between the 2 treatment groups were small and not statistically significant (tables 1 and 2). Of the 366 patients, 89 (24.3%) were frequent IVIG users, and 327 (90%) had been exposed to TMP-SMZ for 13 weeks before enrollment. The 2 treatment groups were balanced with respect to these stratification factors. No obvious differences in acceptability of study drugs were noted, although the placebo preparations were similar in color, taste, and consistency to the respective drugs.
Follow-up
The median durations of follow-up in the intent-to-treat analyses were 160 weeks (∼3.1 years) and 163 weeks (∼3.1 years) for the atovaquone-azithromycin and TMP-SMZ groups, respectively. The median durations of follow-up for the astreated analyses were 95 weeks (∼1.8 years) and 97 weeks (∼1.9 years) for the atovaquone-azithromycin and TMP-SMZ groups, respectively. Fifty-three patients were discontinued from the original treatment regimen. In the atovaquone-azithromycin and TMP-SMZ groups, 21 and 18 patients, respectively, reached end points with serious bacterial infection, PCP, and MAC infections; 9 and 4 patients, respectively, had treatment-related toxicity, and 1 patient (TMP-SMZ) died during their first serious bacterial infection-related event. Overall, 18 of the 366 patients died (9 in the atovaquone-azithromycin arm and 9 in the TMP-SMZ arm) during the entire study period. Three of these deaths occurred while the patient was receiving the originally randomized therapy, with 1 death due to a serious bacterial infection, another due to PCP, and the third due to progressive congestive heart failure that was considered to be a non-treatment-related toxicity. Deaths due to an infectious complication (6 deaths) were treated as serious bacterial infection-, PCP-, or MAC-related events for purposes of analysis; all other deaths were considered to be nonrelated to infection. None of the deaths were related to treatment. AT-AZ recipients TMP-SMZ recipients AT-AZ recipients TMP-SMZ recipients
15 (16) 17 (18) 17 (19) 20 (22) 16 26 (29) 28 (30) 32 (35) 27 (29) All 42 (46) 45 (48) 49 (51) 48 (52) NOTE. The exact P value for comparison between the 2 arms, stratified by age groups, was .6445. AT-AZ, atovaquone-azithromycin; TMP-SMZ, trimethoprim-sulfamethoxazole. Table 4 . Antiretroviral therapy received by subjects at the time of study enrollment and during the study. Therapy at time of enrollment AT-AZ 22 (6) 14 (4) 148 (40) 184 (50) TMP-SMZ 20 (5) 17 (5) 145 (40) 182 (50) Therapy during study AT-AZ 30 (8) 122 (33) 32 (9) 184 (50) TMP-SMZ 38 (10) 115 (31) 29 (8) 182 (50) NOTE.
AT-AZ, atovaquone-azithromycin; PI, protease inhibitor; TMP-SMZ, trimethoprimsulfamethoxazole.
The pattern of CD4 lymphocyte values during the study is shown in table 3. A CD4 lymphocyte percentage of 15% is the breakpoint below which the risk for opportunistic infection is high. The data show that 49 persons (51%) in the atovaquoneazithromycin group and 48 (52%) in the TMP-SMZ group with CD4 lymphocyte percentages of !15% at enrollment had increases to levels of у15% during the study period. Comparison between the 2 arms stratified by age group showed no significant difference ( ). P p .6445 The use of antiretroviral therapy during the study is summarized in table 4. The distribution of patients receiving no therapy, protease inhibitors, and non-protease inhibitor drugs was similar for the 2 arms. The median duration of protease inhibitor therapy, an important component in HAART, was 308 days for the atovaquone-azithromycin group and 276 days for the TMP-SMZ group. Results from the recurrent events model of Anderson and Gill [14] with protease inhibitor drug use as a time-dependent covariant showed that use of protease inhibitors had statistically significant effects on the infection rate. For the treatment arm without protease inhibitors, the estimated coefficient was 0.238 ( ). When the regimen P p .21 included a protease inhibitor, the estimated coefficient was 1.08 ( ). However, the 2 treatment arms were not sig-P p .000012 nificantly different.
End Point Analysis
Intent-to-treat analysis. All end points in the intent-to-treat analysis were counted, except when analyzed using the WLW model [13] . A summary of all serious bacterial infection-, PCP-, and MAC-related events and nonserious bacterial infection-related deaths is presented in table 5. The estimated rates of serious bacterial infection-related events for atovaquoneazithromycin and TMP-SMZ were 17.3 and 24.2 events per 100 person-years, respectively (d, 6.95; 95% CI, Ϫ0.22 to 14.12) (table 6). Blood cultures for the 12 atovaquone-azithromycintreated patients with bacteremia yielded Streptococcus pneumoniae (6 patients), Pseudomonas aeruginosa (2 patients), and Salmonella species, Enterococcus faecalis, Klebsiella species, or coagulase-negative Staphylococcus (1 patient each). In the 7 cultures for patients who were treated with TMP-SMZ, S. pneumoniae was yielded in 5, Serratia species were yielded in 1, and an unidentified bacterium was yielded in 1.
The respective yearly infection rates (based on person-years of follow-up) for the azithromycin-atovaquone and TMP-SMZ arms were 1.76 and 2.07 for the first year, 1.06 and 1.11 for the second year, 0.36 and 0.89 for the third year, and 0.33 and 0.17 for the fourth year. The difference in the yearly infection rate between the 2 arms was not statistically significant (P p , by the Wilcoxon rank sum test). .8893
The estimated rates of all the end points, including and excluding nonserious bacterial infection-related deaths, for atovaquone-azithromycin and TMP-SMZ are shown in table 6. In the WLW analysis for recurrent events, the estimate for the common ratio of the 2 hazard functions for serious bacterial infection-related events was 1.46 (95% CI, 0.97-2.23). The second analysis for recurrent events was done with all end Proven, primary 9 (2) 6 (3) 3 (2) Proven, secondary 4 (1) 4 (2) 0 (0) Mastoiditis, presumptive 2 (0.5) 2 (1)
Presumptive 58 (16) 30 (16) 28 ( (3) 5 (3) 7 (4) No end point event 250 (68) 135 (73) 115 (63) NOTE.
AT-AZ, atovaquone-azithromycin; TMP-SMZ, trimethoprimsulfamethoxazole.
a Three deaths were related to an SBI and are counted in the event subcategories.
points, excluding nonserious bacterial infection-related deaths. The corresponding estimate was 1.47 (95% CI, 0.99-2.20). The Kaplan-Meier estimates for the 2 treatment groups, with respect to only the first event times (including events associated with serious bacterial infection, PCP, or MAC infection), are given in figure 1 , showing a trend in favor of atovaquone-azithromycin ( , by the log rank test). P p .05 As-treated analysis. Data regarding serious bacterial infections, PCP, MAC infection, and treatment-related toxicity, by as-treated analysis, are summarized in table 7. There were no nonserious bacterial infection-, PCP-, or MAC-related deaths in patients while they were receiving their original therapy. The analysis of primary interest was the difference of the event rates per 100 patient-years between the 2 arms. The estimated rates of serious bacterial infection-related events for the atovaquoneazithromycin and TMP-SMZ groups were 12.9 and 18.5 events per 100 person-years, respectively (table 6).
The estimated rates of all end points are given in table 6. Focusing on the recurrent serious bacterial infection events, the WLW model estimate for the common ratio of the 2 hazard functions was 1.36 (95% CI, 0.92-2.04). The second analysis for recurrent events was done with all end point events, excluding drug-related toxicity. The corresponding estimate was 1.39 (95% CI, , using the WLW model. The estimate for efficacy end points and treatment toxicity was 1.25 (95% CI, 0.82-1.89) using the WLW model.
The Kaplan-Meier estimates for the 2 groups, with respect to only the first event (including events related to serious bacterial infection, PCP, or MAC infection) were similar to those of the intent-to-treat analysis ( figure 1) ; however, the 2-sided P value of the log-rank test was .11, and although this showed a trend in favor of atovaquone-azithromycin, it did not demonstrate statistical significance.
Adverse Events
As-treated analysis. In the overall study population, 220 patients (60%) experienced no severe adverse event, 78 (21%) had severe adverse events, 67 (18%) had life-threatening adverse events, and 1 (!1%), died of a non-treatment-related toxicity (progressive congestive heart failure). The Mantel-Haenszel x 2 P value was .34, and Fisher's exact test (table 8) indicated that the difference between the 2 arms was not significant. Some patients were counted in 11 category if they experienced multiple adverse events. The majority of adverse events were abnormal hematological or chemistry values (table 8) . Other severe or worse adverse events included gastrointestinal events, which affected 16 subjects (4%); pain/headache, which affected 12 (3%); and fever, which affected 10 subjects (3%). P values determined using Fisher's exact test showed no significant difference between the 2 arms.
The Kaplan-Meier plots (data not shown) for the time to first severe or worse adverse event in the 2 treatment groups showed no significant difference between the 2 groups (P p , by the log-rank test). The rash-associated adverse events .78 are listed in table 8. Two hundred seventy-three (75%) of the patients experienced no rash or only mild rash, 78 (21%) had moderate rash, and 14 (4%) had severe life-threatening rash. The plot of Kaplan-Meier estimates of the time to the first severe or worse rash-associated adverse event were similar ( , by the log-rank test). P p .13
Intent-to-treat analysis. The results from the intent-totreat analysis were similar to those of the as-treated analysis. 
NOTE.
AT-AZ, atovaquone-azithromycin; SBI, serious bacterial infection; TMP-SMZ, trimethoprim-sulfamethoxazole.
a Includes SBI, Pneumocystis carinii (also referred to as "Pneumocystis jiroveci") pneumonia,
and Mycobacterium avium complex infection. b Non-SBI-related deaths. c Treatment toxicity end points. Figure 1 . Time to first end points (intent-to-treat analysis). There were 184 patients in the azithromycin-atovaquone group (AT/AZ) and 182 patients in the trimethoprim-sulfamethoxazole group (TMP-SMZ) ( , by the log-rank test).
In a comparison of the groups with regard to the number and the proportion of worst-degree adverse events, the MantelHaenzsel x 2 P value was .65, which indicates there was no significant difference between the 2 treatment arms.
A comparison of the hematological abnormalities revealed no significant differences in P values (by Fisher's exact test) between the 2 arms and in the Kaplan-Meier estimates of the time to the first severe or worse hematological adverse events ( , by log-rank test). P p .66
DISCUSSION
The results of the study show that atovaquone-azithromycin is as effective as TMP-SMZ for the prevention of serious bacterial 
NOTE.
AT-AZ, atovaquone-azithromycin; TMP-SMZ, trimethoprim-sulfamethoxazole.
a PCP events after the first event were not counted towards the end points.
infection in HIV-infected children. A marginal advantage for atovaquone-azithromycin is the result of the higher number of patients with sinusitis in the TMP-SMZ group. Up to 25% of children with AIDS have recurrent bacterial infections as their defining illness [15, 16] . Bacterial infections are more common in HIV-infected children than in healthy control subjects [17, 18] . A serious bacterial infection event rate of 54% was observed for children receiving only zidovudine and no TMP-SMZ or IVIG prophylaxis [8] . Dankner et al. [19] analyzed first-event opportunistic infections in 3331 HIVinfected children participating in 13 ACTG studies during the pre-HAART era. Infection rates were 15.1 cases per 100-patient years for serious bacterial infection, 1.3 cases per 100-patient years for PCP, and 1.8 per cases 100-patient years for disseminated MAC infection. Most of the patients at risk for PCP received TMP-SMZ prophylaxis, but prophylaxis for MAC infection was rarely used.
The numbers of PCP-and MAC-related events were too small for meaningful comparisons. Studies involving HIVinfected adults have demonstrated efficacy and safety of TMP-SMZ and atovaquone for prophylaxis and treatment of PCP and of azithromycin for MAC prevention [7, [20] [21] [22] [23] [24] [25] . Early studies showed that, without prophylaxis, PCP may occur in 150% of adults [4] and ∼37% of children [26] with AIDS. Over the 3 years of our study, PCP occurred in 2% of children who were determined to be at high risk for this infection.
Reconstitution or partial reconstitution of immune responses associated with HAART occurred in a portion of the patients during the study, as evidenced by a subsequent increase in CD4 lymphocyte percentage to у15% in one-half of the patients whose percentages were !15% at baseline. The use of protease inhibitors was associated with a progressive decrease in yearly infection rates. The type and extent of antiretroviral therapy and CD4 lymphocyte responses were similar for the 2 treatment arms.
Azithromycin has been used extensively in children without AIDS for treatment of acute otitis media, pneumonia, and streptococcal pharyngitis [27] and for treatment of otitis media in children with HIV infection [17, 18] . The administration of azithromycin prophylactically to adults with HIV infection is effective and safe for prevention of MAC infection [22, 28] . Pharmacokinetic studies in children show that a dosage of 5 mg/kg per day provides tissue concentrations of azithromycin exceeding the MIC for common pathogens [29] and that azithromycin parameters are not significantly affected by atovaquone [30] .
The frequency, timing, and types of adverse events in our study were similar for the atovaquone-azithromycin and TMP-SMZ groups. In adults with AIDS and PCP who were treated with atovaquone or TMP-SMZ, treatment-limiting adverse effects occurred in 9% of the atovaquone-treated patients and 24% of the TMP-SMZ-treated patients [31] . It should also be noted that the majority of the patients in our study were TMP-SMZ experienced before entry; thus, they were already proven to be tolerant of TMP-SMZ. This may partially explain the low rate of adverse reactions to TMP-SMZ observed in this study. Whether this prior experience with TMP-SMZ increased the likelihood for drug-resistant bacteria and P. carinii is not known.
Atovaquone-azithromycin is at least as effective as TMP-SMZ for the prevention of serious bacterial infection and possibly as effective in the prevention of PCP and MAC infection. Its use for routine antimicrobial prophylaxis in patients with AIDS should not supersede use of TMP-SMZ, primarily because atovaquone-azithromycin is ∼100 times more expensive than TMP-SMZ [32] . Nevertheless, atovaquone-azithromycin offers a useful alternative for patients who cannot take TMP-SMZ because of adverse effects and intolerance.
